Abstract
Seventy-one patients suffering from acute myeloid leukaemia (AML) who were already in complete remission and had already received one further course of cytotoxic drugs as consolidation therapy were randomised to receive maintenance chemotherapy alone or the same maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells. The duration of first remission was slightly, but not significantly, longer in those patients who received immunotherapy. This was true also for the duration of survival after relapse. Comparison with other series suggested that the effect of such immunotherapy on duration of survival after relapse is probably real, but did not clearly indicate whether or not any real difference in the first remission duration existed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Freeman C. B., Harris R., Geary C. G., Leyland M. J., MaCiver J. E., Delamore I. W. Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia. Br Med J. 1973 Dec 8;4(5892):571–573. doi: 10.1136/bmj.4.5892.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heyn R. M., Joo P., Karon M., Nesbit M., Shore N., Breslow N., Weiner J., Reed A., Hammond D. BCG in the treatment of acute lymphocytic leukemia. Blood. 1975 Sep;46(3):431–442. [PubMed] [Google Scholar]
- Mathé G., Amiel J. L., Schwarzenberg L., Schneider M., Cattan A., Schlumberger J. R., Hayat M., De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697–699. doi: 10.1016/s0140-6736(69)92648-8. [DOI] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powles R. L., Crowther D., Bateman C. J., Beard M. E., McElwain T. J., Russell J., Lister T. A., Whitehouse J. M., Wrigley P. F., Pike M. Immunotherapy for acute myelogenous leukaemia. Br J Cancer. 1973 Nov;28(5):365–376. doi: 10.1038/bjc.1973.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powles R. L., Russell J., Lister T. A., Oliver T., Whitehouse J. M., Malpas J., Chapuis B., Crowther D., Alexander P. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer. 1977 Mar;35(3):265–272. doi: 10.1038/bjc.1977.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whittaker J. A., Slater A. J. The immunotherapy of acute myelogenous leukaemia using intravenous BCG. Br J Haematol. 1977 Feb;35(2):263–273. doi: 10.1111/j.1365-2141.1977.tb00583.x. [DOI] [PubMed] [Google Scholar]